Abbott, a global healthcare leader, has launched the Navitor Vision valve in India to provide a less invasive treatment option for patients with severe symptomatic aortic stenosis who are at high or extreme surgical risk. The device is the latest advancement in transcatheter aortic valve implantation/replacement (TAVI/TAVR) technology, designed to improve precision and visibility during implantation.

Key Highlights:

• Enhanced Precision:

Navitor Vision introduces three large Vision markers to improve visibility and accuracy during valve implantation.

• Minimally Invasive Alternative:

TAVI procedures offer a safer option for patients unsuitable for open-heart surgery due to age, frailty, or comorbidities.

• Improved Clinical Outcomes:

The dynamic sealing cuff minimizes blood leakage, and large frame cells allow easy access to coronary arteries for future treatment.

• Flexible Treatment Options:

The valve comes in multiple sizes (19 mm to 27 mm) to fit different heart openings (annulus sizes).

• Advanced Delivery System:

Abbott’s FlexNav catheter, designed for small blood vessels (≥5.0 mm), ensures stable and accurate placement.

Statements from Leaders or Officials:
Neeraj Singh, Country Manager, Abbott Structural Heart Business – India:
“For some people, open-heart surgery is considered a high-risk procedure due to age, frailty, or multiple health conditions. TAVI serves as a less invasive alternative to surgical aortic valve replacement, reducing symptoms and improving life expectancy. Abbott’s Navitor Vision valve is an important addition to our treatments for structural heart diseases, offering hope to patients who may not have other treatment choices.”The introduction of Navitor Vision in India is expected to expand treatment options for high-risk aortic stenosis patients, providing greater precision, improved clinical outcomes, and a minimally invasive alternative to traditional surgery. With clinical studies validating its effectiveness, this innovation marks a significant advancement in heart valve disease treatment.